egnite, Inc. Expands into Cardiovascular Disease Supported by New Data on the State of Care for Patients with Atrial Fibrillation
egnite to focus on improving the quality of care for all cardiovascular patients in the U.S.
Read Moreegnite to focus on improving the quality of care for all cardiovascular patients in the U.S.
Read More“This is the first prevalence study out of one of the largest echo databases in the world, underscoring the potential for groundbreaking research from this tremendous resource. Our work expands by an order of magnitude the sample size and generalizability of previous work in a large contemporary cohort.” J. Matthew Brennan, M.D., M.P.H., Associate Professor […]
Read MoreBACKGROUND Valvular heart disease (VHD) is progressive and deadly, requiring timely diagnosis for optimal outcomes1 Prior landmark analyses of VHD prevalence in the United States (US), including the Framingham Heart Study2 and Nkomo et al.3 , have reported notable prevalence of disease However, these analyses were limited in scope (e.g., reporting only valvular regurgitation or […]
Read MoreData To Be Presented at 2022 ACC Annual Meeting Demonstrate Valve Disease is More Common in Women in the U.S...
Read MoreThe CardioCare platform has partnered with healthcare systems extensively to help elevate the standard of structural heart patient care. Data uncovered from this experience have helped us understand what best-in-class patient care looks like nationwide.
Read MoreThe CardioCare platform uses big data analytics and artificial intelligence powered technology to help physicians elevate the standard of patient care.
Read More© 2024 egnite, Inc. All Rights Reserved. egnite, egnite Inc., CardioCare, the heart logo, and the spark logo are trademarks of egnite, Inc. All other trademarks are property of their respective owners.
Privacy Policy Intellectual Property Terms of Use Implementation Kit Careers